Barrington Research Initiates Rosetta Genomics With Outperform

Analysts at Barrington Research initiated coverage on

with a Outperform rating. The target price for Rosetta Genomics is set to $8. Rosetta Genomics shares have dropped 15.23 percent over the past 52 weeks, while the S&P 500 index has surged 11.85 percent in the same period. Rosetta Genomics' shares rose 1.80 percent to $3.40 in pre-market trading.